Survivin and XIAP: Two valuable biomarkers in medullary thyroid carcinoma

British Journal of Cancer

Volumn 114, Issue 4, 2016, Pages 427-434

  Werner, Thomas A ^a   Tamkan Ölcek, Yasemin ^a   Dizdar, Levent ^a   Riemer, Jasmin C ^a   Wolf, Achim ^a,b   Cupisti, Kenko ^a,c   Verde, Pablo E ^a   Knoefel, Wolfram T ^a   Krieg, Andreas ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^b Ingolstadt Medical Center   (Germany)

^c Marien Hospital Euskirchen   (Germany)

Author keywords

apoptosis; biomarker; inhibitor of apoptosis protein; medullary thyroid carcinoma; survivin; XIAP

Indexed keywords

BIOLOGICAL MARKER; CALCITONIN; SURVIVIN; X LINKED INHIBITOR OF APOPTOSIS; BIRC5 PROTEIN, HUMAN; INHIBITOR OF APOPTOSIS PROTEIN; TUMOR MARKER; XIAP PROTEIN, HUMAN;

ADOLESCENT; ADULT; AGED; ARTICLE; CALCITONIN BLOOD LEVEL; CANCER PROGNOSIS; CANCER STAGING; CHILD; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; THYROID MEDULLARY CARCINOMA; TISSUE MICROARRAY; CARCINOMA; IMMUNOHISTOCHEMISTRY; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; THYROID TUMOR; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CARCINOMA, NEUROENDOCRINE; CHILD; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INHIBITOR OF APOPTOSIS PROTEINS; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL RATE; THYROID NEOPLASMS; TISSUE ARRAY ANALYSIS; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN; YOUNG ADULT;

EID: 84962409031     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2016.5     Document Type: Article

References (51)

1. American Thyroid Association Guidelines Task Force Kloos RT, Eng C, Evans DB, Francis GL, Gagel RF, Gharib H, Moley JF, Pacini F, Ringel MD, Schlumberger M, Wells SA. (2009). Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid. 19: 565-612.
2. Ball DW. (2009). American Thyroid Association guidelines for management of medullary thyroid cancer: an adult endocrinology perspective. Thyroid. 19: 547-550.
3. Bertrand MJM, Doiron K, Labbé K, Korneluk RG, Barker PA, Saleh M. (2009). Cellular inhibitors of apoptosis cIAP1 and cIAP2 are required for innate immunity signaling by the pattern recognition receptors NOD1 and NOD2. Immunity. 30: 789-801.
4. Blume-Jensen P, Hunter T. (2001). Oncogenic kinase signalling. Nature. 411: 355-365.
5. Cupisti K, Lehwald N, Anlauf M, Riemer J, Werner TA, Krieg A, Witte J, Chanab A, Baldus SE, Krausch M, Raffel A, Herdter C, Schott M, Knoefel WT. (2014). Encapsulation status of papillary thyroid microcarcinomas is associated with the risk of lymph node metastases and tumor multifocality. Horm Metab Res. 46: 138-144.
6. de Almagro MC, Vucic D. (2012). The inhibitor of apoptosis (IAP) proteins are critical regulators of signaling pathways and targets for anti-cancer therapy. Exp Oncol. 34: 200-211.
7. Donis-Keller H, Dou S, Chi D, Carlson KM, Toshima K, Lairmore TC, Howe JR, Moley JF, Goodfellow P, Wells SA. (1993). Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet. 2: 851-856.
8. Dralle H, Musholt TJ, Schabram J, Steinmüller T, Frilling A, Simon D, Goretzki PE, Niederle B, Scheuba C, Clerici T, Hermann M, Kumann J, Lorenz K, Nies C, Schabram P, Trupka A, Zielke A, Karges W, Luster M, Schmid KW, Vordermark D, Schmoll H-J, Mühlenberg R, Schober O, Rimmele H, Machens A. German Societies of General and Visceral Surgery, Endocrinology, Nuclear, Medicine, Pathology, Radiooncology, Oncological Hematology and the German Thyroid Cancer Patient Support Organization Ohne Schilddrüse leben e.V. (2013). German Association of Endocrine Surgeons practice guideline for the surgical management of malignant thyroid tumors. Langenbecks Arch Surg. 398: 347-375.
9. Elisei R, Cosci B, Romei C, Bottici V, Renzini G, Molinaro E, Agate L, Vivaldi A, Faviana P, Basolo F, Miccoli P, Berti P, Pacini F, Pinchera A. (2008). Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. J Clin Endocrinol Metab. 93: 682-687.
10. Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel RF, van Amstel HK, Lips CJ, Nishisho I, Takai SI, Marsh DJ, Robinson BG, Frank-Raue K, Raue F, Xue F, Noll WW, Romei C, Pacini F, Fink M, Niederle B, Zedenius J, Nordenskjöld M, Komminoth P, Hendy GN, Mulligan LM. (1996). The relationship between specific RET protooncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA. 276: 1575-1579.
11. Goossens-Beumer IJ, Zeestraten ECM, Benard A, Christen T, Reimers MS, Keijzer R, Sier CFM, Liefers GJ, Morreau H, Putter H, Vahrmeijer AL, van de Velde CJH, Kuppen PJK. (2014). Clinical prognostic value of combined analysis of Aldh1, Survivin, and EpCAM expression in colorectal cancer. Br J Cancer. 110: 2935-2944.
12. Gu Y, Jin S, Wang F, Hua Y, Yang L, Shu Y, Zhang Z, Guo R. (2014). Clinicopathological significance of PI3K, Akt and survivin expression in gastric cancer. Biomed Pharmacother. 68: 471-475.
13. Gyrd-Hansen M, Meier P. (2010). IAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and cancer. Nat Rev Cancer. 10: 561-574.
14. Hu MI, Ying AK, Jimenez C. (2014). Update on medullary thyroid cancer. Endocrinol Metab Clin N Am. 43: 423-442.
15. Hussain AR, Bu R, Ahmed M, Jehan Z, Beg S, Al-Sobhi S, Al-Dayel F, Siraj AK, Uddin S, Al-Kuraya KS. (2015). Role of X-linked inhibitor of apoptosis as a prognostic marker and therapeutic target in papillary thyroid carcinoma. J Clin Endocrinol Metab. 100: E974-E985.
16. Ito Y, Kihara M, Hirokawa M, Takamura Y, Kobayashi K, Miya A, Miyauchi A. (2012). Validity of 6th edition of UICC TNM classification system for medullary thyroid carcinoma: a proposal for intraoperative evaluation of T category. Endocr J. 59: 407-416.
17. Krieg A, Baseras B, Tomczak M, Verde PE, Stoecklein NH, Knoefel WT. (2013). Role of survivin as prognostic and clinicopathological marker in gastric cancer: a meta-Analysis. Mol Biol Rep. 40: 5501-5511.
18. Krieg A, Correa RG, Garrison JB, Le Negrate G, Welsh K, Huang Z, Knoefel WT, Reed JC. (2009). XIAP mediates NOD signaling via interaction with RIP2. Proc Natl Acad Sci USA. 106: 14524-14529.
19. Krieg A, Reed JC. (2010). IAPs and their emergent role in NLR signaling. Cell Cycle. 9: 426-427.
20. Krieg A, Werner TA, Verde PE, Stoecklein NH, Knoefel WT. (2013). Prognostic and clinicopathological significance of survivin in colorectal cancer: a meta-Analysis. PLoS One. 8: e65338.
21. Lalami Y, Awada A. (2011). Recurrent thyroid cancer: a molecular-based therapeutic breakthrough. Curr Opin Oncol. 23: 235-240.
22. Leboulleux SS, Baudin EE, Travagli J-PJ, Schlumberger MM. (2004). Medullary thyroid carcinoma. Clin Endocrinol (Oxf) 61: 299-310.
23. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics. (2005). Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst. 97: 1180-1184.
24. Mehrotra S, Languino LR, Raskett CM, Mercurio AM, Dohi T, Altieri DC. (2010). IAP regulation of metastasis. Cancer Cell. 17: 53-64.
25. Mehta A, Zhang L, Boufraqech M, Liu-Chittenden Y, Zhang Y, Patel D, Davis S, Rosenberg A, Ylaya K, Aufforth R, Li Z, Shen M, Kebebew E. (2015). Inhibition of survivin with YM155 induces durable tumor response in anaplastic thyroid cancer. Clin Cancer Res. 21: 4123-4132.
26. Miller LK. (1999). An exegesis of IAPs: salvation and surprises from BIR motifs. Trends Cell Biol. 9: 323-328.
27. Miura K, Fujibuchi W, Ishida K, Naitoh T, Ogawa H, Ando T, Yazaki N, Watanabe K, Haneda S, Shibata C, Sasaki I. (2011). Inhibitor of apoptosis protein family as diagnostic markers and therapeutic targets of colorectal cancer. Surg Today. 41: 175-182.
28. Mizutani Y, Nakanishi H, Li YN, Matsubara H, Yamamoto K, Sato N, Shiraishi T, Nakamura T, Mikami K, Okihara K, Takaha N, Ukimura O, Kawauchi A, Nonomura N, Bonavida B, Miki T. (2007). Overexpression of XIAP expression in renal cell carcinoma predicts a worse prognosis. Int J Oncol. 30: 919-925.
29. Obexer P, Ausserlechner MJ. (2014). X-linked inhibitor of apoptosis protein - A critical death resistance regulator and therapeutic target for personalized cancer therapy. Front Oncol. 4: 197.
30. Qi X-P, Ma J-M, Du Z-F, Ying R-B, Fei J, Jin H-Y, Han J-S, Wang J-Q, Chen X-L, Chen C-Y, Liu W-T, Lu J-J, Zhang J-G, Zhang X-N. (2011). RET germline mutations identified by exome sequencing in a Chinese multiple endocrine neoplasia type 2A/familial medullary thyroid carcinoma family. PLoS One. 6: e20353.
31. R Development Core Team. (2014). R: A Language and Environment for Statistical Computing. The R foundation for statistical computing: Vienna, Austria. Available from http://www.R-project.org/.
32. Ramp U, Krieg T, Caliskan E, Mahotka C, Ebert T, Willers R, Gabbert HE, Gerharz CD. (2004). XIAP expression is an independent prognostic marker in clear-cell renal carcinomas. Hum Pathol. 35: 1022-1028.
33. Remmele W, Hildebrand U, Hienz HA, Klein PJ, Vierbuchen M, Behnken LJ, Heicke B, Scheidt E. (1986). Comparative histological, histochemical, immunohistochemical and biochemical studies on oestrogen receptors, lectin receptors, and Barr bodies in human breast cancer. Virchows Arch A. 409: 127-147.
34. Rosa J, Canovas P, Islam A, Altieri DC, Doxsey SJ. (2006). Survivin modulates microtubule dynamics and nucleation throughout the cell cycle. Mol Biol Cell. 17: 1483-1493.
35. Rödel F, Sprenger T, Kaina B, Liersch T, Rödel C, Fulda S, Hehlgans S. (2012). Survivin as a prognostic/predictive marker and molecular target in cancer therapy. Curr Med Chem. 19: 3679-3688.
36. Schwaederle M, Zhao M, Lee JJ, Eggermont AM, Schilsky RL, Mendelsohn J, Lazar V, Kurzrock R. (2015). Impact of precision medicine in diverse cancers: a meta-Analysis of phase II clinical trials. J Clin Oncol. 33: 3817-25.
37. Selemetjev S, Dencic TI, Marecko I, Jankovic J, Paunovic I, Savin S, Cvejic D. (2014). Evaluation of survivin expression and its prognostic value in papillary thyroid carcinoma. Pathol Res Pract. 210: 30-34.
38. Shi Y-H, Ding W-X, Zhou J, He J-Y, Xu Y, Gambotto AA, Rabinowich H, Fan J, Yin X-M. (2008). Expression of X-linked inhibitor-of-Apoptosis protein in hepatocellular carcinoma promotes metastasis and tumor recurrence. Hepatology. 48: 497-507.
39. Takahashi M. (1995). Oncogenic activation of the ret protooncogene in thyroid cancer. Crit Rev Oncog. 6: 35-46.
40. Tenev T, Bianchi K, Darding M, Broemer M, Langlais C, Wallberg F, Zachariou A, Lopez J, MacFarlane M, Cain K, Meier P. (2011). The Ripoptosome, a signaling platform that assembles in response to genotoxic stress and loss of IAPs. Mol Cell. 43: 432-448.
41. Thomas S, Muralidharan A, Shah GV. (2007). Knock-down of calcitonin receptor expression induces apoptosis and growth arrest of prostate cancer cells. Int J Oncol. 31: 1425-1437.
42. Thomas S, Shah G. (2005). Calcitonin induces apoptosis resistance in prostate cancer cell lines against cytotoxic drugs via the Akt/survivin pathway. Cancer Biol Ther. 4: 1226-1233.
43. Tuttle RM, Ball DW, Byrd D, Daniels GH, Dilawari RA, Doherty GM, Duh Q-Y, Ehya H, Farrar WB, Haddad RI, Kandeel F, Kloos RT, Kopp P, Lamonica DM, Loree TR, Lydiatt WM, McCaffrey J, Olson JA, Parks L, Ridge JA, Shah JP, Sherman SI, Sturgeon C, Waguespack SG, Wang TN, Wirth LJ. (2010). Medullary carcinoma. Compr Cancer. 8: 512-30.
44. Vaux DL, Silke J. (2003). Mammalian mitochondrial IAP binding proteins. Biochem Biophys Res Commun. 304: 499-504.
45. Vitale G, Caraglia M, Ciccarelli A, Lupoli G, Abbruzzese A, Tagliaferri P, Lupoli G. (2001). Current approaches and perspectives in the therapy of medullary thyroid carcinoma. Cancer. 91: 1797-1808.
46. Waligórska-Stachura J, Andrusiewicz M, Sawicka-Gutaj N, Biczysko M, Jankowska A, Kubiczak M, Czarnywojtek A, Wrotkowska E, Ruchaa M. (2014). Survivin delta Ex3 overexpression in thyroid malignancies. PLoS One. 9: e100534.
47. Wan Y, Liu T, Hou X, Dun Y, Guan P, Fang H. (2014). Antagonists of IAP proteins: novel anti-Tumor agents. Curr Med Chem. 21: 3877-3892.
48. Wells SA, Pacini F, Robinson BG, Santoro M. (2013). Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an update. J Clin Endocrinol Metab. 98: 3149-3164.
49. Wu LS, Roman SA, Sosa JA. (2011). Medullary thyroid cancer: an update of new guidelines and recent developments. Curr Opin Oncol. 23: 22-27.
50. Xu Y-C, Liu Q, Dai J-Q, Yin Z-Q, Tang L, Ma Y, Lin X-L, Wang H-X. (2014). Tissue microarray analysis of X-linked inhibitor of apoptosis (XIAP) expression in breast cancer patients. Med Oncol. 31: 764.
51. Yim JH, Kim WG, Jeon MJ, Han JM, Kim TY, Yoon JH, Hong SJ, Song DE, Gong G, Shong YK, Kim WB. (2014). Association between expression of X-linked inhibitor of apoptosis protein and the clinical outcome in a BRAF V600E-prevalent papillary thyroid cancer population. Thyroid. 24: 689-694.